Ultragenyx Pharmaceutical Inc.RARENASDAQ
LOADING
|||
EBITDA Over Time
Below historical average, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$-469.00M
↓ 36% below average
Average (9y)
$-344.69M
Historical baseline
Range
High:$-139.81M
Low:$-640.49M
CAGR
+13.8%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-469.00M | +9.2% |
| 2023 | $-516.45M | +19.4% |
| 2022 | $-640.49M | -56.1% |
| 2021 | $-410.32M | -193.5% |
| 2020 | $-139.81M | +64.1% |
| 2019 | $-389.77M | -119.5% |
| 2018 | $-177.56M | +43.2% |
| 2017 | $-312.51M | -27.8% |
| 2016 | $-244.58M | -67.1% |
| 2015 | $-146.35M | - |